YOUR DAILY PEPTIDE BRIEFING / SCIENCE / COMMUNITYNew source checks every six hours
Daily Peptide StackNEWS • RESEARCH • COMMUNITY
THE NEWS STACK / SOURCE NOTE

Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight.

A source-backed record from the peptide news monitor, with the original source linked below.

BEFORE YOU READ

This page links to the original record; it is not an independent analysis or clinical recommendation.

← Back to Trials Stack
Trials StackClinicalTrials.gov

Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

Clinical trial record NCT06937099 was updated or published. See the registry for its current status, eligibility, and results (if reported).

Open original source ↗

Collected Nov 4, 2026. Third-party data may change. Consult the original publication or registry for complete methods, findings and status.